| The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Klastersky, M Paesmans, EB Rubenstein, M Boyer, L Elting, R Feld, ... Journal of clinical oncology 18 (16), 3038-3051, 2000 | 1480 | 2000 |
| Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference F Roila, J Herrstedt, M Aapro, RJ Gralla, LH Einhorn, E Ballatori, E Bria, ... Annals of Oncology 21, v232-v243, 2010 | 871 | 2010 |
| Management of febrile neutropaenia: ESMO clinical practice guidelines J Klastersky, J De Naurois, K Rolston, B Rapoport, G Maschmeyer, ... Annals of Oncology 27, v111-v118, 2016 | 742 | 2016 |
| Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing … JM Nabholtz, HJ Senn, WR Bezwoda, D Melnychuk, L Deschenes, ... Journal of Clinical Oncology 17 (5), 1413-1413, 1999 | 649 | 1999 |
| 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients F Roila, A Molassiotis, J Herrstedt, M Aapro, RJ Gralla, E Bruera, ... Annals of Oncology 27, v119-v133, 2016 | 584 | 2016 |
| Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting RM Navari, M Aapro New England Journal of Medicine 374 (14), 1356-1367, 2016 | 428 | 2016 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 406 | 2021 |
| Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized … BL Rapoport, K Jordan, JA Boice, A Taylor, C Brown, JS Hardwick, ... Supportive Care in Cancer 18, 423-431, 2010 | 291 | 2010 |
| Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline … M Marty, M Espie, A Llombart, A Monnier, BL Rapoport, V Stahalova, ... Annals of Oncology 17 (4), 614-622, 2006 | 264 | 2006 |
| Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update SM Grunberg, D Osoba, PJ Hesketh, RJ Gralla, S Borjeson, BL Rapoport, ... Supportive care in cancer 13, 80-84, 2005 | 222 | 2005 |
| Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score A Uys, BL Rapoport, R Anderson Supportive care in cancer 12, 555-560, 2004 | 217 | 2004 |
| A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group ME Lacouture, ML Maitland, S Segaert, A Setser, R Baran, LP Fox, ... Supportive Care in Cancer 18, 509-522, 2010 | 201 | 2010 |
| Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin … R De Wit, J Herrstedt, B Rapoport, AD Carides, G Carides, M Elmer, ... Journal of clinical oncology 21 (22), 4105-4111, 2003 | 185 | 2003 |
| Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients … BL Rapoport, MR Chasen, C Gridelli, L Urban, MR Modiano, ID Schnadig, ... The Lancet Oncology 16 (9), 1079-1089, 2015 | 183 | 2015 |
| Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and … LS Schwartzberg, MR Modiano, BL Rapoport, MR Chasen, C Gridelli, ... The Lancet Oncology 16 (9), 1071-1078, 2015 | 179 | 2015 |
| The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a … R de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, ... European Journal of Cancer 40 (3), 403-410, 2004 | 171 | 2004 |
| Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art SM Grunberg, D Warr, RJ Gralla, BL Rapoport, PJ Hesketh, K Jordan, ... Supportive Care in Cancer 19, 43-47, 2011 | 148 | 2011 |
| The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group K El Bairi, HR Haynes, E Blackley, S Fineberg, J Shear, S Turner, ... NPJ breast cancer 7 (1), 150, 2021 | 139 | 2021 |
| Aprepitant and fosaprepitant: a 10-year review of efficacy and safety M Aapro, A Carides, BL Rapoport, HJ Schmoll, L Zhang, D Warr The oncologist 20 (4), 450-458, 2015 | 138 | 2015 |
| Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy BL Rapoport, R Anderson International journal of molecular sciences 20 (4), 959, 2019 | 134 | 2019 |
